Vitamin D3 immune cell therapy for progressive multiple sclerosis
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests a new treatment using a patient's own immune cells, modified with vitamin D3, to try to calm the immune system and slow the progression of multiple sclerosis (MS) without causing major side effects. It is for people with progressive MS who have not had recent relapses.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have a diagnosis of progressive multiple sclerosis (MS) and have not had any relapses in the past 2 years.
- Your disability level is between 2.0 and 7.5 on the EDSS scale (you can walk at least some distance without aid).
- You have not taken certain MS treatments recently (e.g., Tysabri, Gilenya, Tecfidera, or B-cell therapies) and have not had strong immune-suppressing treatments like alemtuzumab or a stem cell transplant in the last 3 years.
- You are not currently on any other MS disease-modifying treatment.
- You are willing to use effective contraception if you could become pregnant or father a child.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental treatment called C-CAR168, which uses your own immune cells that have been modified to target and potentially slow down the progression of multiple sclerosis. It is for younger adults with progressive MS who have not responded well to standard treatments.
This trial tests a new cell therapy called S103 for people with MS that isn't responding well to standard treatments. The therapy involves modifying immune cells in the lab and putting them back into your body to help control the disease.
This trial is testing a type of immunotherapy called CAR-T cells (made from your own immune cells) to see if it can help slow or stop progressive multiple sclerosis. It is a very early safety study, so only people with progressive MS who meet strict health criteria can join.
This study tests a new treatment that combines a type of immune cell therapy with a targeted antibody to see if it can help people with multiple sclerosis. It aims to reduce the immune system's attack on the nervous system and potentially slow disease progression.
This study looks at how well different treatments, including bone marrow transplant, alemtuzumab, ocrelizumab, and ofatumumab, work for people with relapsing-remitting MS who have active disease. It will help doctors understand which therapy might slow disease progression best.
This trial tests a new way to treat primary progressive multiple sclerosis (PPMS) using a stem cell transplant from a healthy donor. The goal is to see if this approach can stop or slow the disease and improve quality of life.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.